Enanta Pharmaceuticals, Inc.

NasdaqGS:ENTA Voorraadrapport

Marktkapitalisatie: US$232.0m

Enanta Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Enanta Pharmaceuticals heeft een totaal eigen vermogen van $148.9M en een totale schuld van $175.6M, wat de schuld-eigenvermogensverhouding op 117.9% brengt. De totale activa en totale passiva bedragen respectievelijk $398.8M en $249.9M.

Belangrijke informatie

117.9%

Verhouding schuld/eigen vermogen

US$175.61m

Schuld

Rente dekkingsration/a
ContantUS$230.09m
AandelenUS$148.92m
Totaal verplichtingenUS$249.91m
Totaal activaUS$398.82m

Recente financiële gezondheidsupdates

Recent updates

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Oct 05
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Jul 24
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Jun 19
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

May 09
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24
We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08
Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Oct 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta starts mid-stage trial of EDP-938 for RSV infection

Oct 03

Enanta Pharma FQ3 2022 Earnings Preview

Aug 07

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Jul 29

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04
Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $286.6M ) ENTA } overtreffen de korte termijn passiva ( $58.2M ).

Langlopende schulden: De kortetermijnactiva ENTA ( $286.6M ) overtreffen de langetermijnschulden ( $191.7M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ENTA heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van ENTA is de afgelopen 5 jaar gestegen van 0.4% naar 117.9%.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ENTA heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: ENTA heeft voldoende kasruimte voor 1.4 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 51.6 % per jaar.


Ontdek gezonde bedrijven